Kazunori Akimoto

Kazunori Akimoto

Auto-generated profile, based on publicly available information

Kazunori Akimoto

Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
STShoma Tamori
Shoma Tamori
YNYuka Nozaki
Yuka Nozaki
HMHitomi Motomura
Hitomi Motomura
HNHiromi Nakane
Hiromi Nakane
RKReika Katayama
Reika Katayama
KAKazunori Akimoto
Kazunori Akimoto
Oncotarget | https://doi.org/10.18632/oncotarget.26369 Shoma Tamori, Yuka Nozaki, Hitomi Motomura, Hiromi Nakane, Reika Katayama, Chotaro Onaga, Eriko Kikuchi, Nami Shimada, Yuhei Suzuki, Mei Noike, Yasushi Hara,... Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells

1 July 2017 in Genes & Cancer
Verified
Journal Article
Open access
YNYuka Nozaki
Yuka Nozaki
STShoma Tamori
Shoma Tamori
MIMasahiro Inada
Masahiro Inada
RKReika Katayama
Reika Katayama
HNHiromi Nakane
Hiromi Nakane
KAKazunori Akimoto
Kazunori Akimoto
C-Met is a receptor-type tyrosine kinase, which is involved in a wide range of cellular responses such as proliferation, motility, migration and invasion. It has been reported to be overexpressed in various cancers. However, the role of c-Met in breast cancer stem cells (CSCs) still remains unclear. We herein, show that c-Met expression is significantly elevated in Basal-like type of breast cancer in comparison with other subtypes. High expression of c-Met strongly correlated with the expression of two CSC markers, ALDH1A3 and CD133 in breast cancers. In addition, breast cancers at tumor stage III-IV expressing both c-Methigh and ALDH1A3high had poor prognosis. Furthermore, treatment with c-Met inhibitors (Crizotinib, Foretinib, PHA-665752 and Tivantinib) in MDA-MB157 cells with high c-Met protein expression resulted in significant suppression in cell viability, contrary to MDA-MB468 cells with low c-Met protein expression. These c-Met inhibitors also suppressed cell viability and tumor-sphere formation of ALDH1high breast cancer cells with high c-Met expression. These results suggest that c-Met in ALDH1 positive CSCs seems to play an important role in breast cancer repopulation. Therefore, we conclude that c-Met is a potential therapeutic target in ALDH1 positive breast CSCs.

8 January 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
COChotaro Onaga
Chotaro Onaga
STShoma Tamori
Shoma Tamori
HMHitomi Motomura
Hitomi Motomura
AOAyaka Ozaki
Ayaka Ozaki
CMChika Matsuda
Chika Matsuda
KAKazunori Akimoto
Kazunori Akimoto
Background/Aim: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. Materials and Methods: Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed. Results: SLC20A1high patients with ER+, claudin-low or basal-like breast cancers showed poor prognoses. SLC20A1high patients treated with radiotherapy had poor clinical outcomes. SLC20A1 knockdown suppressed the viability of MDA-MB 231 (claudin-low), MDA-MB 468 (basal-like) and MCF-7 (ER+) cells, and tumor-sphere formation by ALDH1high cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers. Conclusion: SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.

19 November 2012 in Cancer Science
Verified
Journal Article
Open access
PDF file
YYYohei Yoshihama
Yohei Yoshihama
YIYusuke Izumisawa
Yusuke Izumisawa
KAKazunori Akimoto
Kazunori Akimoto
YSYoshinori Satoh
Yoshinori Satoh
TMTaichi Mizushima
Taichi Mizushima
SOShigeo Ohno
Shigeo Ohno
Overexpression of atypical protein kinase Cλ/ι (aPKCλ/ι), a regulator of cell polarity, is frequently associated with the poor prognoses of several cancers, including gastric cancer. Recent studies revealed a molecular link between aPKC and KIBRA, an upstream regulator of tumor suppressor Hippo pathway that regulates cell proliferation and apoptosis. Further, KIBRA directly inhibits the kinase activity of aPKC to regulate epithelial cell polarity. These observations suggest that the KIBRA‐aPKC connection plays a role in cancer progression; however, clinical significance of the correlation between these factors remains unclear. Here we examined the correlation between KIBRA/aPKCλ/ι expression, as detected by immunohistochemistry, and clinicopathological outcomes in 164 gastric cancer patients using Fisher's exact test and Kaplan–Meier log‐rank test. We found an intimate correlation between the expression level of KIBRA and aPKCλ/ι (P = 0.012). Furthermore, high expression of KIBRA is correlated with lymphatic (P = 0.046) and venous invasion (P = 0.039). The expression level of KIBRA by itself did not correlate with the prognosis; however, high expression of KIBRA in low aPKCλ/ι‐expressing gastric cancer correlated with disease‐specific (P = 0.037) and relapse‐free survival (P = 0.041) by Kaplan–Meier with log‐rank test and higher lymphatic invasion cases by Fisher's exact test (P = 0.042). Furthermore, overexpression of the aPKC‐binding region of KIBRA disrupted tight junctions in epithelial cells. These results suggest that high expression of KIBRA in low aPKC‐expressing cells causes massive loss of aPKC activity, leading to loss of polarity and invasiveness of gastric cancer cells.

31 December 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
HMHitomi Motomura
Hitomi Motomura
YNYuka Nozaki
Yuka Nozaki
COChotaro Onaga
Chotaro Onaga
AOAyaka Ozaki
Ayaka Ozaki
STShoma Tamori
Shoma Tamori
KAKazunori Akimoto
Kazunori Akimoto
Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer.

13 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YNYuka Nozaki
Yuka Nozaki
HMHitomi Motomura
Hitomi Motomura
STShoma Tamori
Shoma Tamori
YKYumiko Kimura
Yumiko Kimura
COChotaro Onaga
Chotaro Onaga
KAKazunori Akimoto
Kazunori Akimoto
Despite development of markers for identification of cancer stem cells, the mechanism underlying the survival and division of cancer stem cells in breast cancer remains unclear. Here we report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test). Late stage breast cancer patients expressing PKCλhigh and ALDH1A3high had poorer disease-specific survival than those expressing PKCλlow and ALDH1A3low (p = 0.018, log rank test for Kaplan-Meier survival curves: hazard ratio 2.58, 95% CI 1.24–5.37, p = 0.011, multivariate Cox regression analysis). Functional inhibition of PKCλ through siRNA-mediated knockdown or CRISPR-Cas9-mediated knockout in ALDH1high MDA-MB 157 and MDA-MB 468 basal-like breast cancer cells led to increases in the numbers of trypan blue-positive and active-caspase 3-positive cells, as well as suppression of tumor-sphere formation and cell migration. Furthermore, the amount of CASP3 and PARP mRNA and the level of cleaved caspase-3 protein were enhanced in PKCλ-deficient ALDH1high cells. An Apoptosis inhibitor (z-VAD-FMK) suppressed the enhancement of cell death as well as the levels of cleaved caspase-3 protein in PKCλ deficient ALDH1high cells. It also altered the asymmetric/symmetric distribution ratio of ALDH1A3 protein. In addition, PKCλ knockdown led to increases in cellular ROS levels in ALDH1high cells. These results suggest that PKCλ is essential for cancer cell survival and migration, tumorigenesis, the asymmetric distribution of ALDH1A3 protein among cancer cells, and the maintenance of low ROS levels in ALDH1-positive breast cancer stem cells. This makes it a key contributor to the poorer prognosis seen in late-stage breast cancer patients.